Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press23710.17650/1726-9776-2011-7-3-70-74DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиEFFICIENCY OF USING A COMBINATION OF AVASTIN AND LOW-DOSE INTERFERON-Α2A IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMAЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ КОМБИНАЦИИ АВАСТИНА С ИНТЕРФЕРОНОМ Α-2А В НИЗКОЙ ДОЗЕ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКАAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruKalpinskyA. S.КалпинскийА. С.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncology Research InstituteМНИОИ им. П.А. Герцена300920117370740308201403082014https://oncourology.abvpress.ru/oncur/article/view/237

Due to the introduction of angiogenesis inhibitors into clinical practice to treat metastatic renal cell carcinoma, the trials dealing with the use of this class of medications are urgent. The paper gives the results of studies of the efficacy of bevacizumab in combination with low-dose interferon-α2a.

В связи с внедрением в клиническую практику лечения метастатического почечно-клеточного рака ингибиторов ангиогенеза представляются актуальными исследования, посвященные применению группы препаратов этого класса. Приводятся результаты исследований эффективности бевацизумаба в комбинации с интерфероном α-2а в низких дозах.

metastatic renal cell carcinomaangiogenesis inhibitorsbevacizumabinterferon αметастатический почечно-клеточный ракингибиторы ангиогенезабевацизумабинтерферон α1. Keane T., Gillatt D., Evans C.P. et al. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6:374−84.Keane T., Gillatt D., Evans C.P. et al. Current and future trends in treatment of renal cancer. Eur Urol 2007;Suppl 6:374−84.2. Cohen H., McGovern F. Renal Cell carcinoma. N Engl J Med 2005; 353:3477–90.Cohen H., McGovern F. Renal Cell carcinoma. N Engl J Med 2005; 353:3477–90.3. Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.4. De Mulder P.H. M., Patard J-J., Szczylik C. et al. Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma. Eur Urol 2007; Suppl 6: 665-671.De Mulder P.H. M., Patard J-J., Szczylik C. et al. Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma. Eur Urol 2007; Suppl 6: 665-671.5. Ljungberg B., Cowan N., Hanbury D.C. et al Guidelines on renal cell cancer. European Association of Urology 2010.Ljungberg B., Cowan N., Hanbury D.C. et al Guidelines on renal cell cancer. European Association of Urology 2010.6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer [v.1.2011] Доступны на http://www.nccn.orgNational Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer [v.1.2011] Доступны на http://www.nccn.org7. Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol 2008; Suppl 7:601−9.Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol 2008; Suppl 7:601−9.8. Patard J.-J. New treatment options for renal cell cancer – critical evaluation. Eur Urol 2008; Suppl 7:443−6.Patard J.-J. New treatment options for renal cell cancer – critical evaluation. Eur Urol 2008; Suppl 7:443−6.9. Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol 2008;Suppl 7:579−84.Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol 2008;Suppl 7:579−84.10. Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633−43.Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633−43.11. Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007;370:2103−11.Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007;370:2103−11.12. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24.13. Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.14. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.15. Motzer R. J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.Motzer R. J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.16. Cora N., Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010 28:1061−68.Cora N., Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010 28:1061−68.17. Бевацизумаб (Авастин). Инструкция по медицинскому применению.Бевацизумаб (Авастин). Инструкция по медицинскому применению.18. Yang J.C, Haworth L, Sherry R.M. et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427−34.Yang J.C, Haworth L, Sherry R.M. et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427−34.19. Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib. J Clin Oncol 2005;23:7889−96.Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib. J Clin Oncol 2005;23:7889−96.20. Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer. J Clin Oncol 2007;25:4536−41.Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer. J Clin Oncol 2007;25:4536−41.21. Escudier B.J., Ravaud A., Bracarda S. et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). 2008 Genitourinary Cancers Symposium. Abstr № 358. www.asco.orgEscudier B.J., Ravaud A., Bracarda S. et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). 2008 Genitourinary Cancers Symposium. Abstr № 358. www.asco.org22. Escudier B.J., Bellmunt J., Negrier S. et al. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol 2010;28:2144−50.Escudier B.J., Bellmunt J., Negrier S. et al. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol 2010;28:2144−50.23. Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab Plus Interferon Alpha Compared with Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422−8.Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab Plus Interferon Alpha Compared with Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422−8.24. Rini B. I., Halabi S., Rosenberg J. E. et al. Phase III Trial of Bevacizumab Plus Interferon-Alpha Versus Interferon-Alpha Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. J Clin Oncol 2010;28:2137−43.Rini B. I., Halabi S., Rosenberg J. E. et al. Phase III Trial of Bevacizumab Plus Interferon-Alpha Versus Interferon-Alpha Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. J Clin Oncol 2010;28:2137−43.25. Hutson T.E., Figlin R.A., Kuhn J.G. et al. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. The Oncologist 2008:13:1084−96.Hutson T.E., Figlin R.A., Kuhn J.G. et al. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. The Oncologist 2008:13:1084−96.26. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. The Oncologist 2011;16:32–44.Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. The Oncologist 2011;16:32–44.27. Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology 2008;19:1470–6.Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology 2008;19:1470–6.28. Melichar B., Bracarda S., Matveev V. et al. BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29(15):suppl:abstr 4546.Melichar B., Bracarda S., Matveev V. et al. BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29(15):suppl:abstr 4546.